FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival

Byooviz Ranibizumab Biosimilar Approved; Company Reveals Launch Date Expectations

 
• By David Wallace
  
OK Sign Eye Woman
The FDA has approved the Byooviz ranibizumab biosimilar to Lucentis • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products